Understand the source comparison
Follistatin-344 vs Follistatin-288: Isoform Selection for Research Protocols
Follistatin exists in multiple isoforms produced by alternative splicing of the FST gene, with Follistatin-344 and Follistatin-288 being the two predominant forms studied in body composition research. The numerical suffix refers to amino acid length. Follistat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Follistatin exists in multiple isoforms produced by alternative splicing of the FST gene, with Follistatin-344 and Follistatin-288 being the two predominant forms studied in body composition research. The numerical suffix refers to amino acid length. Follistatin-344 is the full-length protein, while Follistatin-288 lacks the C-terminal acidic domain, resulting in fundamentally different pharmacokinetics and tissue distribution profiles.
- Follistatin-288 binds heparan sulfate proteoglycans (HSPGs) on cell surfaces and extracellular matrix components with high affinity, effectively sequestering the peptide in local tissue microenvironments. This makes Follistatin-288 ideal for localized interventions. For example, intramuscular injection studies targeting specific muscle groups or wound healing models where localized myostatin inhibition is desired. Half-life is short (approximately 2–4 hours in circulation) because tissue binding rapidly clears the peptide from systemic circulation.
- Follistatin-344 for body composition research, by contrast, lacks the strong heparan sulfate binding affinity due to its intact C-terminal domain, allowing it to circulate freely in the bloodstream with an extended half-life of 12–18 hours in rodent models and an estimated 24–36 hours in primates based on pharmacokinetic modeling. This systemic circulation enables whole-body myostatin inhibition. Every muscle group, organ system, and adipose depot is exposed to the peptide simultaneously. For researchers studying overall body composition changes, metabolic shifts, or multi-tissue anabolic effects, Follistatin-344 is the functionally superior isoform.
- The practical distinction shows up in dosing frequency and total peptide required. A typical Follistatin-344 protocol in murine models involves subcutaneous administration at 100–500 micrograms per kilogram body weight every 48–72 hours, while Follistatin-288 protocols require daily or twice-daily dosing at higher per-dose concentrations to maintain therapeutic tissue levels. The longer half-life also reduces injection-site variability. A significant experimental confound when working with peptides that exhibit localized activity.
- One caveat: Follistatin-344's systemic distribution means off-target effects must be monitored more carefully. Myostatin inhibition in cardiac tissue, for example, has been associated with mild left ventricular hypertrophy in long-duration animal studies. A finding that underscores the importance of dose titration and monitoring in any body composition protocol. Real Peptides supplies both isoforms with third-party purity verification (>98% by HPLC) and exact amino acid sequencing to eliminate experimental confounds related to peptide integrity or contamination.